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Abstract
Over the past 20 years, the number of anemia cases has increased more than 6-fold. Unfortunately, the treatment of pregnant 
women with anemia using an iron supplement gives unsatisfactory results. However, the data from the present study can change 
situation for the better. This conclusion was derived from a comparative analysis of the treatment of 65 pregnant women suffering 
from anemia, divided into two groups: the study and control groups. Patients of the study group received, along with standard 
therapy, courses of hyperbaric oxygenation (HBO). Evaluation of treatment efficiency was based on data from laboratory methods, 
Doppler, and cardiotocography before and after treatment, as well as a morphological study of the placenta. The received results 
show that the use of HBO in the complex treatment of pregnant women with anemia may take place in clinical practice both for 
treatment of anemia during pregnancy, and for the prevention of complications of pregnancy and childbirth.
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Introduction
Anemia and pregnancy is one of the most urgent 
problems of modern obstetrics. According to WHO, it is 
estimated that 41.8% of pregnant women worldwide are 
anemic. At least half of this anemia burden is assumed to be 
due to iron deficiency [1]. Though the role of iron deficiency 
in producing anemia among pregnant women is beyond any 
doubt, unfortunately, treatment of such pregnant women with 
an iron supplement gives comparatively poor results. Despite 
the large amount of research devoted to the study of this 
disease, up to now the downward trends in its frequency were 
not observed [2]. Anemia is highly resistant to any modern 
methods of treatment, and the number of complications it 
causes cannot be compared with any extragenital disease [3]. 
Anemia during pregnancy as an oxygen deficit condition is like 
a clinical model for the study of various aspects of hypoxia in 
the mother and the fetus [4]. Long before pregnancy, anemia 
causes angiopathy of the uterine vessels, which leads to the 
realization of placental insufficiency during pregnancy in these 
women [5]. HBO may compensate a haemoglobin deficiency 
by increasing levels of plasma-dissolved oxygen. Hyperbaric 
therapy was first documented in 1662, when Henshaw built 
the first hyperbaric chamber, or ‘domicilium’ [6]. Since this 
time,  reports  of  beneficial  effects  from  increased  pressure 
have increased, and by 1877, chambers were used widely for 
many conditions, though there was little scientific rationale or 
evidence. 
Research conducted by the US military after the Second 
World War brought greater knowledge about survivable 
pressures. As a result, the use of HBO increased, and 
throughout the late 1950s and early 1960s, HBO was used 
to potentiate radiotherapy effects, prolong circulatory arrest 
during surgery [7], and to treat anaerobic infections [8] and 
carbon  monoxide  poisoning  [9].    Concerns  about  lack  of 
scientific progress and regulation led the UHMS to form a 
Committee on Hyperbaric Oxygen Therapy in the late 1970s, 
which is now the international authority on HBO.
The effects of HBO are based on the gas laws, and the 
physiological and biochemical effects of hyperoxia. HBO 
has complex effects on immunity, oxygen transport and 
haemodynamics. The positive therapeutic effects come from 
a reduction in hypoxia and edema [10]. HBO is a relatively 
safe treatment, but does carry some risks, due to the increased 
pressure and hyperoxia. Clinical and experimental evidence 
does not support claims that HBO during pregnancy can cause 
a range of fetal complications [11,12], including spina bifida 
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and limb defects [13].The only absolute contraindication to 
HBO is an untreated tension pneumothorax, and this must be 
excluded before treatment.
The purpose of the study was to determine the 
effectiveness of HBO courses in the treatment of anemia and 
prevention of perinatal complications in pregnant women.
Material and Methods
We analyzed 65 pregnant women with anemia who 
were treated in the maternity department of Bauman Clinical 
Hospital #29 in Moscow. Informed consent was obtained 
from each patient. The study was approved by the Peoples’ 
Friendship University of Russia and the Bauman Clinical 
Hospital #29 Ethics Committees. 
The study group comprised 40 patients with moderate 
anemia (Hb: 86.5±1.5g/L, erythrocytes: 2.8·1012/L), who, in 
addition to the standard treatment of anemia, received HBO 
sessions. The control group consisted of 25 patients with 
anemia who received only standard treatment. Exclusion 
criteria were the absolute (an untreated pneumothorax) and   
relative contraindications to the use of HBO (a history of 
epilepsy, viral infectios, pacemaker, claustrophobia, etc.). 
Pregnant women of the study group received, besides the 
complex therapy, the HBO sessions (excess air pressure 1.3-
1.5 atm. in a pressure chamber). We used a single-system 
OKA-MT (Russia), equipped with air-conditioning 54–58A 
and designed to conduct sessions in a high-pressure oxygen 
environment. The mode is one excess atmosphere [14]. The 
course includes 5–7 daily sessions lasting 40 minutes each. 
The first course was carried out in 6–8 weeks, the second in 
16–18 weeks, and the third in 22–24 weeks of pregnancy. 
The choice of given periods of pregnancy was determined by 
important stages in the formation of the utero-placental area. 
Since the earliest period of the therapeutic effect on blood flow 
in the utero-placental area to correct the violations may be 
considered 7–8 weeks and 16–18 weeks of gestation until the 
end of the first and second waves of cytotrophoblast invasion. 
Evaluation of treatment efficacy was based on data from 
clinical and laboratory findings before treatment and after its 
completion. The following hardware methods of research were 
performed: ultrasonography (USG) of the woman’s abdomen 
and fetal cardiotocography (CTG) of the fetus. Dynamic 
fetomonitoring was performed daily for all patients during 
treatment in the obstetrics hospital. These data were entered 
into a specially designed card. After birth, the morphological 
study of the placenta was conducted in accordance with 
the order #28 of MoH RF from 29.04.94 (“On the order of 
postmortem studies”).
Assessment of the newborn was done on the Apgar scale 
in the first and fifth minutes of life. Based on this assessment, 
we analyzed the early neonatal period. To assess the degree of 
CNS of a child, a clinical assessment of neurological status 
was made.
Results were statistically processed using the software 
package Statistica 6.0 for Windows. The mean (M) and standard 
deviation (SD)  were deduced. Analysis of the distribution 
of values obtained was performed using the Kolmogorov-
Smirnov test. For data with normal distribution, inter-group 
comparisons were performed using Student’s t-test. A value of 
P<0.05 was considered statistically significant.
Results
The mean age of patients in the study group was 26.5±4.7 
years. The average body weight of patients was 65.6±9.2 kg, 
the average height 163.9±7.1 cm in both groups. It was found 
that primiparas dominated in both groups: 68.1%, vs 31.9% 
for secundiparas. 
In the analysis of extragenital diseases, in addition to 
anemia,  cardiovascular  disease  was  diagnosed  in  3  (7.5%) 
patients of the study group and 6 (24.0%) patients of the 
control group. Respiratory diseases (chronic laryngotracheitis, 
chronic bronchitis) were registered in 7 (17.5%) patients of 
the study group and 5 (20.0%) patients of the control group. 
The diseases of the gastrointestinal tract (chronic gastritis, 
chronic cholecystitis, chronic pancreatitis) were diagnosed in 
11 (27.5%) patients of the study group, and in 7 (28%) patients 
of the control group. Urinary system diseases (chronic cystitis, 
chronic pyelonephritis) were observed in 17 (42.5%) patients 
of the study group and in 19 (76%) patients of the control 
group.
Gynecological  diseases  were  reported  in  37  (56.9%) 
patients in the two groups with the dominance of inflammatory 
disorders of the appendages in 17 (42.5%) patients of the study 
group and in 20 (80%) patients of the control group.
Examination of the course of pregnancy found that the 
threat  of  termination  of  pregnancy  was  significantly  more 
frequent in the control group; it was observed in 15 (60%) 
patients of the control group and in 9 (22.5%) of women who 
received HBO. In the control group, the course of pregnancy 
was complicated by preeclampsia in 14 (56%) cases, while 
in patients receiving HBO preeclampsia was diagnosed in 4 
(10%) cases. Birth occurred vaginally in 83.9% of the study 
group patients and 68.0% of the control group patients. Study 
of childbirth complications revealed the majority cases were 
premature rupture of membranes. This complication occurred 
more often in the control group than in the study group: 8 
(32%) vs 4 (10%) Emergency cesarean section was performed 
in 11 patients: 5 (12.5%) in the study group and 6 (24%) in 
the control group. In the control group, 9 (36%) patients had 
placental insufficiency; primary weakness of labor was found 
in 2 (8%) patients, and narrow pelvis in 1 (4%) patient. In the 
study group, 7 (17.5%) patients had decompensation placental 
insufficiency as a basis for emergency delivery by cesarean 
section. Cesarean section was done in a planned manner (at 
high myopia, retinopathy, uterine muscle scar after prior 
cesarean section, breech presentation of a large fetus) in 7 
(17.5%) patients of the study group and in 10 (40%) patients 
of the control group.  
The treatment of the studied patients in both groups 
caused an increase in hemoglobin levels. This increase 
was more pronounced in the cases of HBO. Before the 
HBO courses, the hemoglobin level in the study group was 
86.5±1.5g/L; after the HBO courses the level was 110.5±1.5g/l 
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hemoglobin level was not statistically changed. Against the 
background of treatment with HBO, there was a significant 
increase in the number of red blood cells by 0.12×1012/l, in the 
platelet count by 9.5×109/l, and in the protein levels by 3.09g/l 
in relation to the indicators in the standard treatment group. 
Dynamics of ferrokinetic indicators in pregnant women are 
shown in Table 1.
After HBO courses in the studied patients, there was 
significant improvement in Doppler data. Indicators of utero- 
and fetoplacental blood flow increased by 32%, whereas in 
the control group patients it increased only by 17%. At the 
application of HBO, cardiotocography parameters were 
improving, showing an increase in amplitude and frequency 
of oscillation and the disappearance of decelerations.
The Apgar score was 7.2±1.3 points in the first minute of 
life and 7.8±1.2 points in the fifth minute of life in newborns 
of control group mothers. Thus, in the first-minute and fifth-
minute the average Apgar score in the study group was 
significantly higher compared to the control group (7.6±0.5 
points and 8.4±0.7 points), P<0.05. 
Conclusion
The essence of HBO is connected with the fast rise of 
oxygen’s strain in tissues due to an increase in the quantity 
of soluble blood oxygen, increasing the speed of diffusion 
between the blood and the hypoxic area of tissue. The source of 
oxygen supply is soluble oxygen in plasma. Under an increase 
in its pressure, the speed of oxygen transfer from blood to 
intertissue liquid is raised and from there to the cells, where 
biological oxidation takes place with the help of enzymes 
[10,14].  Comparative  analyses  of  clinic-laboratory  results 
proved that HBO contributes to improving the functions 
of breathing and blood circulation; improves adaptive 
possibilities of the cardio-vessel system, microcirculation 
and indicators of fetoplacental system; and improves the 
process of erythropoiesis, the course of pregnancy, and the 
period after birth.  The use of HBO in pregnant women with 
anemia contributes to a significant reduction in complications 
of pregnancy, and can significantly improve the condition of 
newborns, reducing perinatal illness [11-12,15-16]. 
Thus, the received results show that the use of HBO in 
the complex treatment of pregnant women with anemia may 
take place in clinical practice both for treatment of anemia 
during pregnancy, and for the prevention of complications of 
pregnancy and childbirth.
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Table 1. 
Dynamics of ferrokinetic indicators during treatment
Variable Group 1
n=40
Group 2
n=25
P*1-2
before after*  before  after* 
Serum Fe,mmol/l 3.9±0.6 13.2±1.9 4.1±0.8 9.0±1.7 <0.001
Ferritin,μg/l 10.3±2.6 19.5±5.1 11.2±1.4 18.3±6.8 >0.05
Transferrin,g/l 4.3±0.19 4.24±0.57 3.9±0.1 3.88±0.2 <0.01